logo
logo

Emulate Closes $82 Million Series E Financing To Scale Amid Rapid Growth In Organ-On-A-Chip Market

Sep 07, 2021•almost 4 years ago

Amount Raised

$82 Million

Round Type

series e

Boston

Description

Emulate, Inc., a leading provider of next generation in vitro models, today announced the close of an $82 million Series E financing round led by existing investor Northpond Ventures with additional participation from Perceptive Advisors. With this investment, Emulate has raised nearly $225 million to date.

Company Information

Company

Emulate

Location

Boston, Massachusetts, United States

About

Emulate is igniting a new era in human health with industry leading organ-on-a-chip technology. The Human Emulation System provides a window into the inner workings of human biology and disease—offering researchers an innovative technology designed to predict human response with greater precision and detail than conventional cell culture or animal-based experimental testing. Pioneered at the Wyss Institute for Biologically Inspired Engineering at Harvard University and backed by Northpond Ventures, Founders Fund, and Perceptive Advisors, researchers across academia, pharma, and government industries are already benefiting from the predictive power of organ-on-a-chip technologies ability to recreate true-to-life human biology.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech